3-substituted N-(arylor heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors

Details for Australian Patent Application No. 2007233928 (hide)

Owner Novartis AG

Inventors Furet, Pascal; Vaupel, Andrea; Imbach, Patricia; Masuya, Keiichi

Agent Davies Collison Cave

Pub. Number AU-A-2007233928

PCT Pub. Number WO2007/113000

Priority 0606805.0 04.04.06 GB

Filing date 2 April 2007

Wipo publication date 11 October 2007

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

16 October 2008 PCT application entered the National Phase

  PCT publication WO2007/113000 Priority application(s): WO2007/113000

27 November 2008 Amendment Made

  The nature of the amendment is: Amend the invention title to read from 3-substituted N-(arylor heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors To: 3-substituted N-(arylor heteroaryl)-pyrazolo[1,5-a]pyrimidines as kinase inhibitors

9 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007233932-Paper substrate comprising vapour deposited triazine, and process and apparatus for making a laminate comprising said substrate

2007233926-3-unsubstituted N-(arylor heteroarvl)-pyrazolori [1,5-a]pyrimidines as kinase inhibitors